# MIMS Philippines

> Drug Information, Disease News

Canonical page: [https://chrome-stats.com/d/id614269048](https://chrome-stats.com/d/id614269048)

## Overview

- **ID:** `id614269048`
- **Platform:** Apple
- **Type:** Apple app
- **Status:** Available
- **Publisher:** MIMS PTE. LTD.
- **Category:** Medical
- **Rating:** 2.70 / 5 (144 ratings)
- **Version:** 3.19.0
- **Last updated:** 2026-08-01
- **First published:** 2013-04-12
- **Size:** 43 MB
- **Data as of:** 2026-09-05
- **Store listing:** [Apple App Store](https://apps.apple.com/ph/app/mims-philippines/id614269048)
- **Privacy policy:** [https://www.mims.com/privacy/](https://www.mims.com/privacy/)

## Description

MIMS Philippines Chrome extension delivers trusted drug information, dosing details, drug interactions, and disease management guidance to clinicians within the browser, enabling fast, point-of-care decisions.

Get Asia-focused medical news and CME updates, plus expert multimedia content from renowned sources to keep your knowledge current. Built on MIMS’s 50+ years of clinical experience, this extension supports busy healthcare professionals on the go.

## Rankings

- #144,251 — Overall

## Similar extensions and apps

- [MIMS Singapore](https://chrome-stats.com/d/id623779697) — 4.50 / 5
- [MIMS Malaysia](https://chrome-stats.com/d/id614154128) — 3.80 / 5
- [MIMS Indonesia](https://chrome-stats.com/d/id623777196)
- [MIMS Hong Kong](https://chrome-stats.com/d/id623781834) — 3.40 / 5
- [MIMS Thailand](https://chrome-stats.com/d/id614248982) — 4.00 / 5
- [CIMS India](https://chrome-stats.com/d/id965057905) — 2.00 / 5
- [eMIMSplus Asia](https://chrome-stats.com/d/id6745163411)
- [MIMS Education](https://chrome-stats.com/d/id1638340506)
- [eMIMSelite](https://chrome-stats.com/d/id6477411434)
- [eMIMSplus](https://chrome-stats.com/d/id1630697739)
- [iMIMS NZ (New)](https://chrome-stats.com/d/id995129190) — 1.60 / 5
- [Medix Asia](https://chrome-stats.com/d/id6473505091) — 4.90 / 5

---

Source: [Chrome-Stats](https://chrome-stats.com/d/id614269048)
